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PREAMBLE
The American College of Cardiology/American Heart Asso-
ciation (ACC/AHA) Task Force on Practice Guidelines
makes every effort to avoid any actual, potential, or perceived
conﬂict of interest that might arise as a result of an industry
relationship or personal interest of the writing committee.
Speciﬁcally, all members of the writing committee, as well as
peer reviewers of the document, were asked to provide disclo-
sure statements of all such relationships that might be per-
ceived as real or potential conﬂicts of interest. These statements
are reviewed by the parent task force, reported orally to all
members of the writing committee at each meeting, and
updated and reviewed by the writing committee as changes
occur. Please see Appendix 1 for author relationships with
industry and Appendix 2 for peer reviewer relationships with
industry.
These guidelines attempt to deﬁne practices that meet the
needs of most patients in most circumstances. These guideline
recommendations reﬂect a consensus of expert opinion after a
thorough review of the available, current scientiﬁc evidence and
are intended to improve patient care. If these guidelines are
used as the basis for regulatory/payer decisions, the ultimate
goal is quality of care and serving the patient’s best interests.
The ultimate judgment regarding care of a particular patient
must be made by the healthcare provider and patient in light of
all the circumstances presented by that patient.
Sidney C. Smith Jr., MD, FACC, FAHA
Chair, ACC/AHA Task Force on Practice Guidelines
Elliot M. Antman, MD, FACC, FAHA
Immediate Past-Chair, ACC/AHA Task Force on
Practice Guidelines
1. INTRODUCTION
1.1. Purpose of the Expedited Update
Since the publication of the previous guidelines on periopera-
tive cardiovascular evaluation for noncardiac surgery in 2002,
the issue of perioperative beta blockade for non-cardiac surgery
has taken on increased importance. Speciﬁcally, the Physicians
Consortium for Performance Improvement and the Surgical
Care Improvement Project have both identiﬁed perioperative
beta blockade as a quality measure. Given the importance of
these quality measures for both public reporting and eventual
pay-for-performance, and the recent series of publications on
the subject, it became imperative to update the recommenda-
tions related to beta blockade. Therefore, we have chosen to
expedite the review of the literature on perioperative beta
blockade in order to produce recommendations that can be
used in these national quality initiatives. In general, ACC/
AHA Class I and III indications for therapy identify potential
dimensions of care and processes for performance measure-
ment; however, not all Class I and III guidelines recommen-
dations should be selected for performance measurement (1).
Furthermore, Class IIa and Class IIb recommendations are not
considered for stand-alone measures.
Please note that the full 2002 Guideline on Perioperative
Cardiovascular Evaluation for Noncardiac Surgery is being
updated and represents current ACC/AHA policy, with the
exception of the text and tables in the perioperative beta-
blocker therapy section. This focused update replaces the
beta-blocker section in the 2002 Guideline and is consid-
ered current ACC/AHA policy until the update of the full
guideline is published. Please note that Table 2, “Clinical
Predictors of Increased Perioperative Cardiovascular Risk,”
is currently under review and may be modiﬁed as part of the
update of the full guideline.
1.2. Organization of Committee and Evidence Review
The Committee to Update the 2002 Guidelines on Perioper-
ative Cardiovascular Evaluation for Noncardiac Surgery: Fo-
cused Update on Perioperative Beta-Blocker Therapy reviewed
the literature relevant to perioperative cardiac evaluation since
the last publication of these guidelines in 2002. Literature
searches were conducted in PubMed/MEDLINE. Searches
were limited to the English language, 2002 through 2006, and
human subjects. In addition, related-article searches were
conducted in MEDLINE to ﬁnd further relevant articles.
Finally, committee members recommended applicable articles
outside the scope of the formal searches.
As a result of these searches, 23 published articles and 1
abstract were identiﬁed and reviewed by the committee for
the expedited update of the Beta-Blocker section. Using
evidence-based methodologies developed by the ACC/
AHA Task Force on Practice Guidelines, the committee
updated the guideline text and recommendations.
These classes summarize the recommendations for pro-
cedures or treatments as follows:
• Class I: Conditions for which there is evidence for
and/or general agreement that the procedure or treat-
ment is beneﬁcial, useful, and effective.
• Class II: Conditions for which there is conﬂicting
evidence and/or a divergence of opinion about the
usefulness/efﬁcacy of a procedure or treatment.
Class IIa: Weight of evidence/opinion is in favor of
usefulness/efﬁcacy.
Class IIb: Usefulness/efﬁcacy is less well established by
evidence/opinion.
• Class III: Conditions for which there is evidence and/or
general agreement that the procedure/treatment is not
useful/effective, and in some cases may be harmful.
In addition, the weight of evidence in support of the
recommendation is listed as follows:
• Level of Evidence A: Data derived from multiple,
randomized, clinical trials.
• Level of Evidence B: Data derived from a single-
randomized trial or non-randomized studies.
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Figure 1. Applying classiﬁcation of recommendations and level of evidence.
2664 Circulation June 6, 2006
 by guest on Septem
ber 24, 2017
http://circ.ahajournals.org/
D
ow
nloaded from
 
• Level of Evidence C: Only consensus opinion of experts,
case studies, or standard-of-care.
A recommendation with Level of Evidence B or C does not
imply that the recommendation is weak. Many important
clinical questions addressed in guidelines do not lend them-
selves to clinical trials. Although randomized trials are not
available, there may be a very clear clinical consensus that a
particular test or therapy is useful and effective. The schema for
classiﬁcation of recommendations and level of evidence is
summarized in Figure 1, which also illustrates how the grading
system provides an estimate of the size of the treatment effect
and an estimate of the certainty of the treatment effect.
Please note the use of bold-faced type in the recommen-
dations shows where the intent of the recommendation
has changed from the 2002 ACC/AHA Guideline
Update on Perioperative Cardiovascular Evaluation for
Noncardiac Surgery. The bold-faced type only high-
lights changes to the recommendations; it does not show
changes to supporting text, tables, and ﬁgures.
The Committee consisted of acknowledged experts in
general cardiology as well as persons with recognized
expertise in more specialized areas including anesthesiology,
cardiovascular surgery, echocardiography, electrophysiology,
interventional cardiology, nuclear cardiology, vascular med-
icine, and vascular surgery; both academic and private
sectors were represented. The following organizations as-
signed ofﬁcial representatives: the Society for Vascular
Medicine and Biology, American Society of Nuclear Car-
diology, Heart Rhythm Society, Society for Vascular Sur-
gery, American Society of Echocardiography, Society of
Cardiovascular Anesthesiologists, and the Society for Car-
diovascular Angiography and Interventions.
This document was reviewed by 2 ofﬁcial reviewers
nominated by the ACC; 2 ofﬁcial reviewers nominated by
the AHA; 1 ofﬁcial reviewer from the ACC/AHA Task
Force on Practice Guidelines as well as reviewers from the
Society for Vascular Medicine and Biology, American Society
of Nuclear Cardiology, Heart Rhythm Society, American
Society of Echocardiography, Society of Cardiovascular
Anesthesiologists, and the Society for Cardiovascular An-
giography and Interventions; and 20 content reviewers,
including members from American College of Cardiology
Foundation (ACCF) Cardiac Catheterization Committee,
ACCF Peripheral Vascular Disease Committee, ACCF
Cardiovascular Clinical Imaging Committee, ACCF Echo-
cardiography Committee, ACCF Clinical Electrophysiol-
ogy Committee, AHA Council on Cardiopulmonary Peri-
operative and Critical Care Leadership Committee, AHA
Council on Cardiovascular Surgery and Anesthesia Leader-
ship Committee, and the AHA Council on Clinical Car-
diology, Electrocardiography, and Arrhythmias Committee.
2. PERIOPERATIVE MEDICAL THERAPY
2.1. Perioperative Beta-Blocker Therapy
Recommendations for Beta-Blocker Medical Therapy
(Table 1):
Class I
1. Beta blockers should be continued in patients undergo-
ing surgery who are receiving beta blockers to treat
angina, symptomatic arrhythmias, hypertension, or
other ACC/AHA Class I guideline indications.
(Level of Evidence: C)
2. Beta blockers should be given to patients undergoing
vascular surgery at high cardiac risk owing to the ﬁnding
of ischemia on preoperative testing. (Level of Evidence: B)
Class IIa
1. Beta blockers are probably recommended for patients
undergoing vascular surgery in whom preoperative as-
sessment identiﬁes coronary heart disease. (Level of
Evidence: B)
2. Beta blockers are probably recommended for patients
in whom preoperative assessment for vascular surgery
identiﬁes high cardiac risk as deﬁned by the presence
of multiple clinical risk factors.* (Level of Evidence: B)
Table 1. Recommendations for Perioperative Beta-Blocker Therapy Based on Published Randomized Clinical Trials
Low Cardiac
Patient Risk
Intermediate Cardiac
Patient Risk
CHD or High Cardiac
Patient Risk
Patients found to have myocardial
ischemia on preoperative testing
Vascular Surgery Class IIb
Level of Evidence: C
Class IIb
Level of Evidence: C
Class I*
Level of Evidence: B
Class IIa†
Level of Evidence: B
High-/Intermediate-Risk
Surgery
‡ Class IIb
Level of Evidence: C
Class IIa
Level of Evidence: B
Low-Risk Surgery ‡ ‡ ‡
*Applies to patients found to have coronary ischemia on preoperative testing. †Applies to patients found to have coronary heart disease. ‡Indicates insufﬁcient data. See text for
further discussion.
CHD  coronary heart disease.
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3. Beta blockers are probably recommended for patients
in whom preoperative assessment identiﬁes coronary
heart disease or high cardiac risk as deﬁned by the
presence of multiple clinical risk factors* and who are
undergoing intermediate- or high-risk procedures as
deﬁned in these guidelines. (Level of Evidence: B)
Class IIb
1. Beta blockers may be considered for patients who are
undergoing intermediate- or high-risk procedures as
deﬁned in these guidelines, including vascular sur-
gery, in whom preoperative assessment identiﬁes
intermediate cardiac risk as deﬁned by the presence of
a single clinical risk factor.* (Level of Evidence: C)
2. Beta blockers may be considered in patients under-
going vascular surgery with low cardiac risk (as
deﬁned in these guidelines) who are not currently on
beta blockers. (Level of Evidence: C)
Class III
1. Beta blockers should not be given to patients undergo-
ing surgery who have absolute contraindications to beta
blockade. (Level of Evidence: C)
*Please see Table 2, Clinical Predictors of Increased Periop-
erative Cardiovascular Risk, for an explanation of the
clinical risk factors. High cardiac risk includes patients with
major and intermediate clinical predictors. Care should be
taken in applying recommendations on beta-blocker therapy
to patients with decompensated heart failure, nonischemic
cardiomyopathy, high-degree AV block, or severe valvular
heart disease in the absence of coronary heart disease.
2.1.1. Summary of evidence. Despite several meta-
analyses, some reaching conﬂicting conclusions, there are
still very few randomized trials of medical therapy before
noncardiac surgery to prevent perioperative cardiac compli-
cations. The studies that have been conducted in this area
have largely focused on beta-blocker therapy; however, there
remain many limitations to the available data. Few studies
have compared different beta-blocker agents or character-
ized their dose effect in the perioperative setting. Even fewer
have included a protocol for the titration of therapy to effect
(e.g., target heart rate), or examined regimens that include a
preoperative trial of beta-blocker therapy. Studies to deter-
mine the ideal target population, ideal dose, and route are
lacking. In addition, the practical limitations such as how,
when, how long, and by whom perioperative beta-blocker
therapy is ideally or practically implemented remain unad-
dressed. Randomized, controlled trials are still needed to
explore the observation that there may be some harm
associated with beta-blocker therapy in low-risk patients
(3). Moreover, there is currently a lack of data regarding
which beta blocker to use perioperatively. Some observa-
tional data suggest that perioperative death or myocardial
infarction (MI) rates may differ when different beta-blockers
are given perioperatively (4). In summary, the best approach
on how to medically protect patients from cardiovascular
complications during noncardiac surgery is still unknown.
Limitations in the Perioperative Beta-Blocker Literature:
• Most trials are inadequately powered.
• Few randomized trials of medical therapy to prevent
perioperative major adverse cardiac events have been
performed.
• Few randomized trials have examined titration of therapy
to effect (e.g., target heart rate).
• Few randomized trials have examined the role of periop-
erative beta-blocker therapy.
• Studies to determine the role of beta blockers in
intermediate- and low-risk populations are lacking.
• Studies to determine the optimal type of beta blockers are
lacking.
• No studies have addressed care-delivery mechanisms in
the perioperative setting, identifying how, when, and by
whom perioperative beta-blocker therapy should be im-
plemented and monitored.
Although many of the randomized, controlled trials of
beta-blocker therapy are small, the weight of evidence—
especially in aggregate—suggests a beneﬁt to perioperative
beta blockade during noncardiac surgery, particularly in
high-risk patients. Current studies suggest that beta block-
Table 2. Clinical Predictors of Increased Perioperative
Cardiovascular Risk (Myocardial Infarction, Heart Failure,
Death)
Major
Unstable coronary syndromes
● Acute or recent MI* with evidence of important ischemic risk by
clinical symptoms or noninvasive study
● Unstable or severe† angina (Canadian Class III or IV)‡
Decompensated heart failure
Signiﬁcant arrhythmias
● High-grade atrioventricular block
● Symptomatic ventricular arrhythmias in the presence of underlying
heart disease
● Supraventricular arrhythmias with uncontrolled ventricular rate
Severe valvular disease
Intermediate
Mild angina pectoris (Canadian Class I or II)
Previous MI by history or pathological Q waves
Compensated or prior heart failure
Diabetes mellitus (particularly insulin-dependent)
Renal insufﬁciency
Minor
Advanced age
Abnormal ECG (left ventricular hypertrophy, left bundle-branch block,
ST-T abnormalities)
Rhythm other than sinus (e.g., atrial ﬁbrillation)
Low functional capacity (e.g., inability to climb one ﬂight of stairs with
a bag of groceries)
History of stroke
Uncontrolled systemic hypertension
*The American College of Cardiology National Database Library deﬁnes recent MI as
greater than 7 days but less than or equal to 1 month (30 days); acute MI is within
7 days. †May include “stable” angina in patients who are unusually sedentary.
‡Campeau et al. (2).
ECG  electrocardiogram; MI  myocardial infarction.
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ers reduce perioperative ischemia and may reduce the risk of
MI and death in high-risk patients. Available evidence
suggests, but does not deﬁnitively prove that, when it is
possible, beta blockers should be started several days or
weeks before elective surgery, with the dose titrated to
achieve a resting heart rate between 50 and 60 beats per
min, to assure that the patient is indeed receiving the beneﬁt
of beta blockade and should continue during the intraoper-
ative and postoperative period to maintain a heart rate less
than 80 beats per min (5). Several prospective, randomized
trials are either underway or soon to be presented. These
will hopefully shed light on some of the questions regarding
perioperative beta-blocker therapy. Per the ACC/AHA
Task Force on Practice Guidelines methodology, unpub-
lished data cannot be used to formulate guideline
recommendations.
Two randomized trials examined the effect of periopera-
tive beta blockers on cardiac events surrounding surgery.
Poldermans et al. (5) examined the effect of bisoprolol on
patients undergoing vascular surgery and in patients at
high-risk for perioperative cardiac complications scheduled
for vascular surgery. Of 846 patients with risk factors for
cardiac disease, 173 patients were found to have new
regional wall motion abnormalities (RWMA) on dobut-
amine stress echocardiogram (DSE). Of these patients, 61
were excluded from further study owing to large areas
(greater than or equal to 5 segments) of RWMA on DSE or
because they were already taking beta blockers. The remain-
ing 112 high-risk patients were randomized to standard care
or bisoprolol started at least 7 days preoperatively and
titrated to maintain heart rate less than 60 beats per min
preoperatively and less than 80 beats per min intraopera-
tively and postoperatively. The rates of cardiac death (3.4%
vs. 17%; p  0.02) and nonfatal MI (0% vs. 17%; p less than
or equal to 0.001) were lower for the bisoprolol versus
placebo groups, respectively. Importantly, due to the un-
blinded design and inclusion of only high-risk patients in
this study, the results cannot be generalized to all patients
undergoing noncardiac surgery.
Boersma et al. (6) subsequently reanalyzed the total cohort
of 1,351 consecutive patients considered for enrollment in the
aforementioned randomized trial of bisoprolol. Forty-ﬁve pa-
tients had perioperative cardiac death or nonfatal MI. A total
of 83% of patients had fewer than three clinical risk factors.
Among this subgroup, patients receiving beta blockers had a
lower risk of cardiac complications (0.8% [2 of 263]) than those
not receiving beta blockers (2.3% [20 of 855]). In patients with
three or more risk factors (17%), those taking beta blockers
who had a DSE demonstrating four or fewer segments of new
wall-motion abnormalities had a signiﬁcantly lower incidence
of cardiac complications (2.3% [2 of 86]) compared with those
not receiving beta-blocker therapy (9.9% [12 of 121]). How-
ever, among the small group of patients with more extensive
ischemia on DSE (ﬁve or more segments), there was no
difference in the incidence of cardiac events (4 of 11 for those
taking beta blockers versus 5 of 15 for those not taking beta
blockers). Therefore, beta-blocker therapy was beneﬁcial in all
but the subset of patients with more extensive ischemia.
Nevertheless, one must be cautious about inferring a class effect
from this observation about bisoprolol and treatment protocol.
The Multicenter Study of Perioperative Ischemia research
group (7,8) reported on 200 patients undergoing general
surgery randomized to a combination of intravenous and
oral atenolol versus placebo for 7 days. Although they found
no difference in perioperative MI or death, they reported
signiﬁcantly fewer episodes of ischemia by Holter monitor-
ing (24% vs. 39%; p  0.03) in the atenolol versus placebo
groups, respectively. They then followed these patients after
discharge and documented fewer deaths in the atenolol
group over the subsequent 6 months (1% vs. 10%; p less
than 0.001). It is not clear why such a brief course of therapy
could exert such a delayed effect, and the study did not
control for other medications given either before or after
surgery. Angiotensin-converting enzyme inhibitor and beta-
blocker use preoperatively differed signiﬁcantly between the
study groups.
Additional studies have examined the use of perioperative
beta blockers but are limited in power to detect cardiac events
or are not randomized. Stone et al. (9) randomized a group of
patients with mild hypertension who underwent predomi-
nantly (58%) vascular surgery to oral beta blockers 2 h before
surgery or standard care. Control subjects had a higher fre-
quency (28%) of ST-segment depression (on intraoperative
monitoring, as reported by the authors) than treated patients
(2%). In a nonrandomized study, Pasternack et al. (10) gave
oral metoprolol immediately before surgery, followed postop-
eratively by intravenous metoprolol during abdominal aortic
aneurysm repair. Only 3% suffered an acuteMI compared with
18% for matched controls. Pasternack et al. (11) subsequently
reported fewer episodes of intraoperative ischemia in patients
treated with oral metoprolol before peripheral vascular surgery
compared with untreated patients. Yeager et al. (12) reported a
case-control analysis of their experience with perioperative MI
during vascular surgery, comparing 53 index cases of periop-
erative MI with 106 matched controls. They found a strong
association of beta-blocker use with a decreased likelihood of
MI (odds ratio  0.43; p  0.01). Raby et al. (13) demon-
strated in 26 vascular surgery patients with documented pre-
operative ischemia and randomized to a protocol of heart rate
suppression with intravenous esmolol compared to standard
care that the esmolol group had fewer episodes of ischemia
than controls (33% vs. 73%; p  0.055). Zaugg et al. (14)
randomized elderly noncardiac surgery patients to preoperative
and postoperative atenolol titrated to heart rate and intraoper-
ative atenolol titrated to heart rate or no beta blockers, and
detected no episodes of intraoperative myocardial ischemia,
electrocardiographic changes consistent with MI, or death in
any group. Three (of 19) patients in the no beta-blocker group
developed signiﬁcant elevations of cardiac troponin-I consis-
tent with a perioperative MI compared with 0 (of 40) patients
who received one of the atenolol groups. Brady et al. (15)
randomized patients undergoing elective vascular surgery to
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either metoprolol 50 mg twice per day or placebo, from
admission to hospital, until 7 days postoperatively. They found
no difference in cardiovascular events, which included MI,
unstable angina, ventricular tachycardia, and stroke. This trial
may have been underpowered (n 103) to identify a difference
in outcomes, particularly hard outcomes of death and MI.
Also, by trial design, therapy was initiated the day before
vascular surgery, and it is quite possible that those randomized
to metoprolol received incomplete beta blockade in the early
perioperative period.
Perioperative beta-blocker therapy has been reviewed in
several meta-analyses and in a very large cohort population
study. Auerbach and Goldman (16) undertook a review of this
topic in 2002. They reported on a MEDLINE search and
literature review of only ﬁve studies. (All ﬁve studies are
included in Table 3.) They calculated a number needed to
treat, on the basis of these studies, of only 2.5 to 6.7 to see
improvement in measures of myocardial ischemia, and only 3.2
to 8.3 in studies reporting a signiﬁcant impact of beta blockers
on cardiac or all-cause mortality. They concluded that the
literature supports a beneﬁt of beta blockers on cardiac
morbidity.
A systematic review of the perioperative medical therapy
literature by Stevens et al. (17) for noncardiac surgery
included the results of 11 trials using beta blockers for
perioperative therapy. These authors concluded that beta-
blockers signiﬁcantly decreased ischemic episodes during
and after surgery. Beta blockers signiﬁcantly reduced the
risk of nonfatal MI; however, the results became nonsig-
niﬁcant if the two most positive trials were eliminated.
Likewise, the risk of cardiac death was signiﬁcantly
decreased with beta-blocker usage. It should be noted
that these authors incorporated studies not considered in
other meta-analyses, including studies that were not
blinded. Results to be quantiﬁed were limited to those in
the 30-day perioperative period. The authors also re-
ported a direct relationship between the prevalence of
prior MI and the magnitude of risk reduction observed
with beta-blocker therapy, suggesting that higher risk
confers greater beneﬁt. The number needed to prevent
perioperative ischemia was 8 patients, the number needed
to prevent MI was 23, and 32 subjects must be treated to
prevent cardiac death. These authors point out that,
given the observation that high-risk patients seem to
receive all the beneﬁt, the target population for beta-
blocker therapy is not clear. They also highlighted that
schedules of beta-blocker administration varied signiﬁ-
cantly among the reported studies and the potential for a
single large strongly positive study to skew the results of
this meta-analysis.
In contrast, Devereaux et al. (18) published their opinion
paper on the clinical evidence regarding the use of beta-
blocker therapy in patients undergoing noncardiac surgery
for the purpose of preventing perioperative cardiac compli-
cations. They expressed the opinion that the literature
supporting use of beta blockers during noncardiac surgery is
modest at best, based on a few small, unblinded studies with
a focused patient population. In a review of the literature in
2005, Devereaux et al. (19) discussed 22 studies randomiz-
ing 2,437 patients undergoing noncardiac surgery to beta-
blocker therapy or placebo. The POBBLE study was not
included in this review (14). They found no statistically
signiﬁcant beneﬁt on any of the individual outcomes and a
“nominally” statistically signiﬁcant beneﬁt (relative risk of
0.44 with 95% conﬁdence interval [CI] 0.20 to 0.97, 99%
CI 0.16 to 1.24) for the composite outcome of cardiovas-
cular mortality, nonfatal MI, and nonfatal cardiac arrest.
The authors felt these data were inadequate to draw
conclusions and that a larger, controlled study is indicated
before conclusions can be made. This review, however,
included a wide variety of studies, patient populations, and
beta-blocker regimens. Many of the studies described only a
single or double dose of beta blocker preoperatively or at
induction of anesthesia. Much of the data, therefore, does
not pertain to perioperative beta blockade for the purpose of
cardiac risk reduction or focused on a low-risk population.
Additionally, the largest studies included—that is, those
reported by Miller et al. (20) and preliminary data from
Yang et al. (21), which together account for almost as many
subjects as all other studies combined—may not have been
appropriate to include in this analysis. The ﬁrst, by Miller et
al. (20), was a study of a single intravenous dose of beta
blocker for the purpose of blood pressure control during
intubation, not reduction of perioperative events. It in-
cluded follow-up only to the point of discharge from the
recovery room. The second, that of Yang et al. (21), has yet
to be published and, therefore, has not undergone formal
peer review. The studies included in this review also vary
widely in length of follow-up.
McGory et al. (22) performed a meta-analysis of six ran-
domized trials of perioperative beta blockade and concluded
that therapy was associated with signiﬁcant reductions in
perioperative myocardial ischemia (33% to 15%), MI, cardiac
mortality, and long-term cardiac mortality (12% to 2%). These
authors used the combined data to derive odds ratios and CIs
for several outcomes. For perioperative overall mortality the
odds ratio for beta-blocker therapy was 0.52 (95% CI 0.20 to
1.35), and for perioperative cardiac mortality the odds ratio was
0.25 (95% CI 0.07 to 0.87). Neither the POBBLE study nor
the unpublished ﬁndings included in the Devereaux et al. (19)
paper were included, explaining the marked difference in
ﬁndings from the other meta-analysis.
A cohort study by Lindenauer et al. (23) reviewed records
from over 700,000 patients undergoing noncardiac surgery at
329 hospitals in the United States. Participant hospitals in this
cohort study were members of a consortium database measur-
ing quality and health care use. These authors evaluated all
noncardiac surgical cases, and compared those who received
beta blockers within the ﬁrst 2 days of hospitalization with
those who did not receive beta blockers during the ﬁrst 2
hospital days. The authors used propensity score matching
techniques in an attempt to reduce bias. These authors found
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that for a revised cardiac risk index score (24) of three or more
(based on the presence of history of ischemic heart disease,
cerebrovascular disease, renal insufﬁciency, diabetes mellitus, or
a patient undergoing high-risk surgery), patients who received
beta blockers were signiﬁcantly less likely to die in hospital.
This was not true for those with a revised risk index of 2, l, or
0. Those with a risk index of 0 were more likely to die in
hospital if given a beta blocker on Day 1 or Day 2 of
hospitalization. This study is retrospective and not randomized
and, therefore, is subject to potential bias. This is particularly
true in terms of reporting bias, as the documentation was based
entirely on administrative data sets, using arbitrary deﬁnitions
of “on” or “off” perioperative beta blockers, based solely on
hospital day of use. Nonetheless, there appears to be an
association between improved outcomes and the use of beta
blockers in clinically high-risk patients.
Finally, one recent observational cohort study examined the
question of which beta blocker may be best for perioperative
medical therapy. Redelmeier et al. (4) reviewed administrative
data related to elective surgery in Ontario, Canada, and
documented perioperative beta-blocker usage from April 1992
to April 2002 (10 years). They limited their analysis to patients
over the age of 65 years, who were receiving either atenolol or
metoprolol before and after surgery and identiﬁed 37,151
subjects. A total of 1,038 suffered either a perioperative MI or
death, and the rate of MI or death was signiﬁcantly lower
among those patients receiving atenolol versus metoprolol
(2.5% vs. 3.2%, p less than 0.001). This difference persisted
even after adjusting for demographic, clinical, and surgical
factors. The inclusion of other long-acting beta blockers in the
analysis yielded an identical risk reduction. These data suggest
that long-acting beta blockade (when therapy is initiated before
surgery) may be superior to short-acting beta blockade. These
observations await clinical trial evaluation.
REFERENCES
1. Spertus JA, Eagle KA, Krumholz HM, et al. American College of
Cardiology and American Heart Association methodology for the
selection and creation of performance measures for quantifying the
quality of cardiovascular care. J Am Coll Cardiol 2005;45:1147–56.
2. Campeau L. Grading of angina pectoris (letter). Circulation 1976;54:
522–3.
3. Lindenauer PK, Pekow P, Wang K, Mamidi DK, Gutierrez B,
Benjamin EM. Perioperative beta-blocker therapy and mortality after
major noncardiac surgery. N Engl J Med 2005;353:349–61.
4. Redelmeier D, Scales D, Kopp A. Beta-blockers for elective surgery in
elderly patients: population based, retrospective cohort study. BMJ
2005;331:932.
5. Poldermans D, Boersma E, Bax JJ, et al. The effect of bisoprolol on
perioperative mortality and myocardial infarction in high-risk patients
undergoing vascular surgery. Dutch Echocardiographic Cardiac Risk
Evaluation Applying Stress Echocardiography Study Group (see
comments). N Engl J Med 1999;341:1789–94.
6. Boersma E, Poldermans D, Bax JJ, et al. Predictors of cardiac
events after major vascular surgery: role of clinical characteristics,
dobutamine echocardiography, and beta-blocker therapy. JAMA
2001;285:1865–73.
7. Mangano DT, Layug EL, Wallace A, Tateo I. Effect of atenolol on
mortality and cardiovascular morbidity after noncardiac surgery. Mul-
ticenter Study of Perioperative Ischemia Research Group (see com-
ments) (published erratum appears in N Engl J Med 1997;336:1039).
N Engl J Med 1996;335:1713–20.
8. Wallace A, Layug B, Tateo I, et al. Prophylactic atenolol reduces
postoperative myocardial ischemia. McSPI Research Group (see com-
ments). Anesthesiology 1998;88:7–17.
9. Stone JG, Foex P, Sear JW, Johnson LL, Khambatta HJ, Triner L.
Myocardial ischemia in untreated hypertensive patients: effect of a
single small oral dose of a beta-adrenergic blocking agent. Anesthesi-
ology 1988;68:495–500.
10. Pasternack PF, Imparato AM, Baumann FG, et al. The hemodynam-
ics of beta-blockade in patients undergoing abdominal aortic aneurysm
repair. Circulation 1987;76:III1–7.
11. Pasternack PF, Grossi EA, Baumann FG, et al. Beta-blockade to
decrease silent myocardial ischemia during peripheral vascular surgery.
Am J Surg 1989;158:113–6.
12. Yeager RA, Moneta GL, Edwards JM, Taylor LM Jr., McConnell
DB, Porter JM. Reducing perioperative myocardial infarction follow-
ing vascular surgery. The potential role of beta-blockade. Arch Surg
1995;130:869–72.
13. Raby KE, Brull SJ, Timimi F, et al. The effect of heart rate control on
myocardial ischemia among high-risk patients after vascular surgery
(see comments). Anesth Analg 1999;88:477–82.
14. Zaugg M, Tagliente T, Lucchinetti E, et al. Beneﬁcial effects from
beta-adrenergic blockade in elderly patients undergoing noncardiac
surgery. Anesthesiology 1999;91:1674–86.
15. Brady AR, Gibbs JS, Greenhalgh RM, Powell JT, Sydes MR.
Perioperative beta-blockade (POBBLE) for patients undergoing in-
frarenal vascular surgery: results of a randomized double-blind con-
trolled trial. J Vasc Surg 2005;41:602–9.
16. Auerbach AD, Goldman L. Beta-blockers and reduction of cardiac
events in noncardiac surgery: scientiﬁc review. JAMA 2002; 87:
1435–44.
17. Stevens RD, Burri H, Tramer MR. Pharmacologic myocardial pro-
tection in patients undergoing noncardiac surgery: a quantitative
systematic review. Anesth Analg 2003; 7:623–33.
18. Devereaux PJ, Yusuf S, Yang H, Choi PT, Guyatt GH. Are the
recommendations to use perioperative beta-blocker therapy in patients
undergoing noncardiac surgery based on reliable evidence? CMAJ
2004;171:245–7.
19. Devereaux PJ, Beattie WS, Choi PT, et al. How strong is the evidence
for the use of perioperative beta-blockers in non-cardiac surgery?
Systematic review and meta-analysis of randomised controlled trials.
BMJ 2005;331:313–21.
20. Miller DR, Martineau RJ, Wynands JE, Hill J. Bolus administration of
esmolol for controlling the haemodynamic response to tracheal intubation: the
Canadian Multicentre Trial. Can J Anaesth 1991;38:849–58.
21. Yang H, Raymer K, Butler R, Parlow J, Roberts R, Tech M. Metoprolol
after Vascular Surgery (MaVS) (abstr). Can J Anaesth 2004;51:A7.
22. McGory ML, Maggard MA, Ko CY. A meta-analysis of perioperative
beta-blockade: what is the actual risk reduction? Surgery 2005;138:
171–9.
23. Lindenauer PK, Pekow P, Wang K, Mamidi DK, Gutierrez B,
Benjamin EM. Perioperative beta-blocker therapy and mortality after
major noncardiac surgery. N Engl J Med 2005;353:349–61.
24. Lee TH, Marcantonio ER, Mangione CM, et al. Derivation and
prospective validation of a simple index for prediction of cardiac risk of
major noncardiac surgery. Circulation 1999;100:1043–9.
25. Urban MK, Markowitz SM, Gordon MA, Urquhart BL, Kligﬁeld P.
Postoperative prophylactic administration of beta-adrenergic blockers
in patients at risk for myocardial ischemia. Anesth Analg 2000;90:
1257–61.
2670 Circulation June 6, 2006
 by guest on Septem
ber 24, 2017
http://circ.ahajournals.org/
D
ow
nloaded from
 
APPENDIX 1. Author Relationships With Industry for the ACC/AHA Guideline Update on Perioperative
Cardiovascular Evaluation for Noncardiac Surgery: Focused Update on Perioperative Beta-Blocker Therapy
Committee Member Consultant Research Grant
Scientiﬁc
Advisory Board Speakers’ Bureau Other
Joshua A. Beckman, MD ● Bristol-Myers Squibb None ● Sanoﬁ-Aventis ● Bristol-Myers Squibb
● Merck
● Eli Lilly
● Sanoﬁ-Aventis
None
Kenneth A. Brown, MD None None None None None
Hugh Calkins, MD None None None None None
Elliott Chaikof, MD None None None None None
Kirsten E. Fleischmann,
MD, MPH
None None None None ● Pﬁzer (QI/CME
Initiatives)
Lee A. Fleisher, MD None None None None None
William K. Freeman, MD None None None None None
James B. Froehlich, MD,
MPH
● Pﬁzer None ● Sanoﬁ-Aventis ● Sanoﬁ-Aventis
● Otsuka
● Pﬁzer
● Merck
None
Edward K. Kasper, MD None None None None None
Judy R. Kersten, MD ● Abbott Laboratories ● Abbott Laboratories None ● Abbott Laboratories
Barbara Riegel, DNSc, RN None None None None None
John F. Robb, MD None None None None None
APPENDIX 2. External Peer Reviewer Relationships With Industry for the ACC/AHA Guideline Update on
Perioperative Cardiovascular Evaluation for Noncardiac Surgery: Focused Update on Perioperative Beta-
Blocker Therapy*
Peer Reviewer† Representation Research Grant
Speakers’
Bureau/Honoraria Stock Ownership
Consultant/
Advisory Board Other
Dr. Peter Alagona ● Ofﬁcial Reviewer–
Board of Trustees
(BOT)
None None None None None
Dr. Joseph Alpert ● Ofﬁcial Reviewer–
AHA Reviewer
None None None None None
Dr. Vincent Carr ● Ofﬁcial Reviewer–
Board of
Governors (BOG)
None None None None None
Dr. Ray Gibbons ● Ofﬁcial Reviewer–
AHA Reviewer
● Radiant Medical
● Boston Scientiﬁc
● Boehringer Ingelheim
● Spectranetrics
● KAI Pharmaceuticals
● TargeGen
● TherOx
● King Pharmaceuticals
None None ● Hawaii Biotech
● Cardiovascular
Clinical Studies
(WOMEN
study, TIMI
37 A)
● Consumers
Union
None
Dr. Bruce Lytle ● Ofﬁcial Reviewer–
ACCF/AHA
Task Force
Practice Guidelines
None None ● Johnson & Johnson None None
Dr. Susan
Begelman
● Organizational
Reviewer–Society
for Vascular
Medicine and
Biology (SVMB)
None ● Bristol-Myers Squibb
● Sanoﬁ-Aventis
● GlaxoSmithKline
None ● Bristol-Myers
Squibb
● Sanoﬁ-Aventis
● GlaxoSmithKline
None
Continued on next page
Fleisher et al ACC/AHA Perioperative Guideline—Update on Beta-Blocker Therapy 2671
 by guest on Septem
ber 24, 2017
http://circ.ahajournals.org/
D
ow
nloaded from
 
APPENDIX 2 Continued
Peer Reviewer† Representation Research Grant
Speakers’
Bureau/Honoraria Stock Ownership
Consultant/
Advisory Board Other
Dr. Simon Body ● Organizational
Reviewer–Society
of Cardiovascular
Anesthesiologists
(SCA)
● Content Reviewer–
AHA Council on
Cardiopulmonary,
Perioperative and
Critical care
None None None None None
Dr. Bengt Herweg ● Organizational
Reviewer–Heart
Rhythm Society
(HRS)
None None None None None
Dr. Scott Kinlay ● Organizational
Reviewer–Society
for Vascular
Medicine and
Biology (SVMB)
● Pﬁzer ● Pﬁzer
● Merck
None ● Pﬁzer None
Dr. Richard Page ● Organizational
Reviewer–Heart
Rhythm Society
(HRS)
● Content Reviewer-
ACCF Clinical
Electrophysiology
Committee
● Content Reviewer–
AHA Council on
Clinical Cardiology
Electrocardiography
and Arrhythmias
Committee
None None None ● Procter and
Gamble
Pharmaceuticals
None
Dr. Mark Turco ● Organizational
Reviewer–Society
for Cardiovascular
Angiography and
Interventions
(SCAI)
None ● Boston Scientiﬁc
Corp.
● Medtronic
None ● Boston
Scientiﬁc Corp.
● Medtronic
None
Dr. Neil Weissman ● Organizational
Reviewer–American
Society of
Echocardiography
(ASE)
● Edwards Life
Sciences
● Carbomedics
● Wyeth
● Bristol-Myers Squibb
Medical Imaging
● Cook Corp.
● Boston Scientiﬁc
● Arbor Surgical
● Arena Pharmaceutical
● Mitsubishi
None None ● Wyeth
● Pﬁzer
● Bristol-Myers
Squibb Medical
Imaging
● Boston
Scientiﬁc
None
Dr. Kim Williams ● Organizational
Reviewer–American
Society of Nuclear
Cardiology
(ASNC)
● Content Reviewer–
ACCF
Cardiovascular
Clinical Imaging
Committee
● Bristol-Myers Squibb
● CV Therapeutics
● GE Healthcare
● Astellas Pharma
None ● GE Healthcare ● King
Pharmaceuticals
(Expert Reader)
Dr. Mazen Abu-
Fadel
● Content Reviewer–
ACCF Cardiac
Catheterization
Committee
None None None None None
Dr. Ralph Bolman ● Content Reviewer–
AHA Council on
Cardiovascular
Surgery and
Anesthesia
None None None None None
Continued on next page
2672 Circulation June 6, 2006
 by guest on Septem
ber 24, 2017
http://circ.ahajournals.org/
D
ow
nloaded from
 
APPENDIX 2 Continued
Peer Reviewer† Representation Research Grant
Speakers’
Bureau/Honoraria Stock Ownership
Consultant/
Advisory Board Other
Dr. Mark Carlson ● Content Reviewer–
ACCF Clinical
Electrophysiology
Committee
None ● Medtronic ● AtriCure, Inc. ● St. Jude
● Guidant
None
Dr. Leslie Cho ● Content Reviewer–
ACCF Peripheral
Vascular Disease
Committee
● Bristol-Myers Squibb
● Aventis-Sanoﬁ
● Bristol-Myers Squibb
● Aventis-Sanoﬁ
None None None
Dr. Jose Diez ● Content Reviewer–
ACCF Cardiac
Catheterization
Committee
None None None None None
Dr. J. Kevin
Donahue
● Content Reviewer–
AHA Council on
Clinical Cardiology
Electrocardiography
and Arrhythmias
Committee
None None None None None
Dr. Leonard
Dreifus
● Content Reviewer–
ACCF Clinical
Electrophysiology
Committee
None None None ● Merck None
Dr. N.A. Mark
Estes
● Content Reviewer–
AHA Council on
Clinical Cardiology
Electrocardiography
and Arrhythmias
Committee
None ● Medtronic
● Guidant
● St. Jude Medical
None ● Medtronic None
Dr. A. Marc
Gillinov
● Content Reviewer–
AHA Council on
Cardiovascular
Surgery and
Anesthesia
None ● Edwards Life
Sciences
None ● AtriCure, Inc. None
Dr. Loren Hiratzka ● Content Reviewer–
AHA Council on
Cardiovascular
Surgery and
Anesthesia
None None None None None
Dr. Lawrence Katz ● Content Reviewer–
ACCF
Echocardiography
Committee
None None None None None
Dr. Smadar Kort ● Content Reviewer–
ACCF
Echocardiography
Committee
None None None None None
Dr. Peter Kowey ● Content Reviewer–
ACCF Clinical
Electrophysiology
Committee
None None None None None
Dr. Fred Krainin ● Content Reviewer–
ACCF Cardiac
Catheterization
Committee
None None ● Boston Scientiﬁc
● Johnson & Johnson
● Medtronic
None None
Dr. Christopher
Kramer
● Content Reviewer–
ACCF
Cardiovascular
Clinical Imaging
Committee
● Astellas
● Novartis
● GE Healthcare None ● GE Healthcare
● Novartis
● Siemens
Medical
Solutions
(Research
Support)
Continued on next page
Fleisher et al ACC/AHA Perioperative Guideline—Update on Beta-Blocker Therapy 2673
 by guest on Septem
ber 24, 2017
http://circ.ahajournals.org/
D
ow
nloaded from
 
APPENDIX 2 Continued
Peer Reviewer† Representation Research Grant
Speakers’
Bureau/Honoraria Stock Ownership
Consultant/
Advisory Board Other
Dr. Jerrold Levy ● Content Reviewer–
AHA Council on
Cardiovascular
Surgery and
Anesthesia
None None None ● Bayer
● Dyax
● Alexion
Pharmaceuticals
(Steering
Committee for
pexellizumab)
● Novo Nordisk
FXIII (Steering
Committee for
FXIII)
Dr. M. Sean
McMurry
● Content Reviewer–
AHA Council on
Cardiopulmonary,
Perioperative and
Critical Care
None None None None None
Dr. Charanjit Rihal ● Content Reviewer–
ACCF Cardiac
Catheterization
Committee
● Cardiac Dimensions None None ● Millennium None
Dr. Carlos Ruiz ● Content Reviewer–
ACCF Cardiac
Catheterization
Committee
None None None None None
Dr. Frank Sellke ● Content Reviewer–
AHA Council on
Cardiovascular
Surgery and
Anesthesia
None ● Bayer Corporation None ● CereMedix
● Inotek
Corporation
None
Dr. Janet Wyman ● Content Reviewer–
ACCF Cardiac
Catheterization
Committee
None None None None None
This table represents the relationships of peer reviewers with industry that were disclosed at the time of peer review of this guideline. It does not necessarily reﬂect relationships
with industry at the time of publication. *Participation in the peer review process does not imply endorsement of the document. †Names are listed in alphabetical order within
category of review.
2674 Circulation June 6, 2006
 by guest on Septem
ber 24, 2017
http://circ.ahajournals.org/
D
ow
nloaded from
 
Lytle, Rick Nishimura, Richard L. Page and Barbara Riegel
Faxon, Valentin Fuster, Jonathan L. Halperin, Loren F. Hiratzka, Sharon A. Hunt, Bruce W.
Jr, Alice K. Jacobs, Cynthia D. Adams, Jeffrey L. Anderson, Elliott M. Antman, David P. 
Froehlich, Edward K. Kasper, Judy R. Kersten, Barbara Riegel, John F. Robb, Sidney C. Smith,
Brown, Hugh Calkins, Elliott Chaikof, Kirsten E. Fleischmann, William K. Freeman, James B. 
WRITING COMMITTEE MEMBERS, Lee A. Fleisher, Joshua A. Beckman, Kenneth A.
Angiography and Interventions, and Society for Vascular Medicine and Biology
Rhythm Society, Society of Cardiovascular Anesthesiologists, Society for Cardiovascular
American Society of Echocardiography, American Society of Nuclear Cardiology, Heart 
Cardiovascular Evaluation for Noncardiac Surgery): Developed in Collaboration With the
Practice Guidelines (Writing Committee to Update the 2002 Guidelines on Perioperative 
of the American College of Cardiology/American Heart Association Task Force on
Noncardiac Surgery: Focused Update on Perioperative Beta-Blocker Therapy: A Report 
ACC/AHA 2006 Guideline Update on Perioperative Cardiovascular Evaluation for
Print ISSN: 0009-7322. Online ISSN: 1524-4539 
Copyright © 2006 American Heart Association, Inc. All rights reserved.
is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231Circulation 
doi: 10.1161/CIRCULATIONAHA.106.176009
2006;113:2662-2674Circulation. 
 http://circ.ahajournals.org/content/113/22/2662
World Wide Web at: 
The online version of this article, along with updated information and services, is located on the
 /content/113/22/e846.full.pdf
An erratum has been published regarding this article. Please see the attached page for: 
  
 http://circ.ahajournals.org//subscriptions/
is online at: Circulation  Information about subscribing to Subscriptions:
  
 http://www.lww.com/reprints
 Information about reprints can be found online at: Reprints:
  
document. Permissions and Rights Question and Answer this process is available in the
click Request Permissions in the middle column of the Web page under Services. Further information about
Office. Once the online version of the published article for which permission is being requested is located, 
 can be obtained via RightsLink, a service of the Copyright Clearance Center, not the EditorialCirculationin
 Requests for permissions to reproduce figures, tables, or portions of articles originally publishedPermissions:
 by guest on Septem
ber 24, 2017
http://circ.ahajournals.org/
D
ow
nloaded from
 
Please note that the 2002 ACC/AHA Guideline Update on Perioperative Cardiovascular
Evaluation for Noncardiac Surgery [Eagle KA, Berger PB, Calkins H, Chaitman BR, Ewy GA,
Fleischmann KE, Fleisher LA, Froehlich JB, Gusberg RJ, Leppo JA, Ryan T, Schlant RC,Winters
WL Jr. ACC/AHA guideline update for perioperative cardiovascular evaluation for noncardiac
surgery: a report of the American College of Cardiology/American Heart Association Task Force
on Practice Guidelines (Committee to Update the 1996 Guidelines on Perioperative Cardiovas-
cular Evaluation for Noncardiac Surgery). Published in 2002 at www.americanheart.org and
www.acc.org.] has been updated with a focused update on perioperative beta-blocker therapy. The
updated recommendation, “ACC/AHA 2006 Guideline Update on Perioperative Cardiovascular
Evaluation for Noncardiac Surgery: Focused Update on Perioperative Beta-Blocker Therapy: A
Report of the American College of Cardiology/American Heart Association Task Force on
Practice Guidelines (Writing Committee to Update the 2002 Guidelines on Perioperative
Cardiovascular Evaluation for Noncardiac Surgery),” has been published in the June 6, 2006,
issues of Circulation (Circulation. 2006;113:2662–2674) and the Journal of the American College
of Cardiology (J Am Coll Cardiol. 2006;47:2343–2355). This focused update replaces the
recommendations, text, and table on perioperative beta-blocker therapy in the 2002 guideline.
DOI: 10.1161/CIRCULATIONAHA.106.175995
(Circulation. 2006;113:e846.)
© 2006 American Heart Association, Inc.
Circulation is available at http://www.circulationaha.org
e846
Correction
